

REGENERATION. REWIRING. RECOVERY



NurExone  
biologic

Investor Presentation  
Canada (TSXV: NRX) | Germany (J90)



# DISCLAIMER

Contents of this presentation are provided for general information purposes only and do not constitute an offer to sell or solicitation of an offer to buy any security in any jurisdiction.

This presentation contains “forward-looking information” for purposes of applicable securities laws (“forward-looking statements”). Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations or assumptions regarding the future of our business, future plans and strategies, our operational results and other future conditions. Forward-looking statements can be identified by words such as “anticipate”, “believe”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “seek”, “target”, “potential”, “will”, “would”, “could”, “should”, “continue”, “contemplate” and other similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this presentation and include statements regarding our intentions, beliefs or current expectations concerning, among other things, our financial performance, financial condition, liquidity, prospects, growth, strategies and the industry in which we operate. This forward-looking information includes, among other things, statements relating to: expectations regarding industry trends, overall market growth rates and our growth rates and growth strategies; our business plans and strategies; expectations regarding growth; our competitive position in our industry.

Although we base the forward-looking statements contained in this presentation on assumptions that we believe are reasonable, we caution you that actual results and developments (including our financial performance, financial condition and liquidity, and the development of the industry in which we operate) may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. Despite a careful process to prepare and review the forward-looking statements, there can be no assurance that the underlying opinions, estimates, and assumptions will prove to be correct. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future.

## **United States Securities Laws:**

This presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of NurExone Biologic Inc in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities of NurExone Biologic Inc have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, "U.S. persons," as such term is defined in Regulation S under the U.S. Securities Act, unless an exemption from such registration is available.

NurExone does not declare and/or insure and/or imply on any specific result of any treatment which may be developed in the future based on the research and development process done or planned to be done by the Company.

# SNAPSHOT

## Corporate ID

NurExone Biologic Inc. is a publicly-traded biopharmaceutical company, listed on the Toronto Stock Exchange and Frankfurt Stock Exchange. The company is developing and commercializing exosome-based therapies and a production platform for a global market projected at **\$5.2 billion dollars**.

## Business Model

NurExone operates according to two business lines – Development of a first exosome-based therapy for acute **Spinal Cord Injuries (SCI)**. In parallel, the company plans to monetize its proprietary exosome technology and production platform through licensing to the global biopharmaceutical industry for other diseases and indications.

## Team

Management is led by CEO, **Dr. Lior Shaltiel**, an awarded scientist with extensive multidisciplinary international experience. The company's team includes **Dr. Lyora Aharonov**, R&D Director, an expert in biological research and a scientific advisory board led by world-renowned **Prof. Shulamit Levenberg**, and **Prof. Nahshon Knoller**, the former head of the neurosurgery department in the largest hospital in Israel, that led 3 clinical SCI studies.

## Mission

To revolutionize **recovery** from nervous system injuries by **regenerating** and **rewiring** of neurons.



# UNLEASHING THE POWER OF EXOSOMES

Introducing NurExone Biologic Inc.

**NurExone is an Israel-based biopharmaceutical company at the forefront of exosome-based therapeutics research and development, with a focus on revolutionizing recovery from Central Nervous System (CNS) injuries.**

Our first product is been developed to be a minimally invasive therapy for **acute Spinal Cord Injuries (SCI)**. Our proprietary exosome therapy has the potential to fundamentally change the way medicine is delivered.

## OUR SOLUTION AND FIRST PRODUCT

Targeting Acute SCI





One of the key assets of NurExone's technology is its drug delivery system, **ExoTherapy**.

**ExoPTEN**, the first ExoTherapy product, which is designed to treat acute spinal cord injuries, has shown promising initial results in preclinical studies **for neuron regeneration** in rats model.



# ExoPTEN, OUR FIRST EXOTHERAPY PRODUCT

Preclinical study results

| MRI IMAGING OF MICE SPINAL CORD  | TIMING  | POST 56 DAYS           |
|--|---|------------------------|
| <p>Healthy</p>      | Beginning of experiment   | Full functionality     |
| <p>Transection</p>  | Following the complete transection of the spinal cord                         | Full paralysis         |
| <p>Exosome</p>     | Exosome only (control)  | None                   |
| <p>ExoPTEN</p>    | Intranasal Exo-PTEN administration – <b>synergistic between control group</b> | Restored functionality |



NUREXONE  
AT A GLANCE

---



## INVEST IN A PROMISING FUTURE

NurExone operates according to two business lines, one of which is ready to start generating revenue.

**Portfolio Company:** One of the key assets of NurExone's technology is its proprietary therapeutic product, ExoPTEN targeting treatment of acute spinal cord injuries as the first indication,. It has a significant market opportunity as a potential Orphan Drug Designation (ODD). The global market for acute spinal cord injury is \$2.9bn by 2027\*.

**Platform Technology Company:** In addition to its use within the company, NurExone also plans to monetize the proprietary exosome production and loading platform and technology by licensing it to other companies within the global biopharmaceutical industry for other diseases and indications. The global market for Exosome based diagnostics and therapeutics, projected at reaching \$2.3bn by 2030\*\*.






## CHARTING A PATH TO SUCCESS

Plans for commercialization, expansion,  
and collaboration

- NurExone has obtained an exclusive worldwide license from the Technion and Tel Aviv University to develop and commercialize the exosome technology that has been under development for 10+ years.
- NurExone has submitted several patent applications in the United States and other key markets under the Patent Cooperation Treaty (PCT). A first patent has been allowed by the USPTO.
- NurExone began operations in 2020, and is focused on optimizing the its proprietary exosomes production process and preparations towards commercialization of its ExoPTEN drug for acute SCI.



# THE SCIENCE BEHIND NUREXONE

---

# LEVERAGING EXOSOMES TO CREATE OUR SOLUTION AND PRODUCT


What are Exosomes?

**Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells.**

Exosomes have a unique ability to ferry “cargo” to specific cells and inflamed tissue, while navigating extracellular spaces and penetrating cell membranes.

## OUR FORMULA:


Leveraging exosomes to produce ExoTherapy



Exosomes



Therapeutic Compounds  
(Modified siRNA)




ExoTherapy

# UNLOCKING THE THERAPEUTIC POTENTIAL OF EXOSOMES

Advantages for Acute SCI

**How does NurExone's exosome-based technology differ from other approaches being used to treat acute Spinal Cord Injuries (SCI)?**

- *Exosomes can be administered non-invasively, intranasally (through the nose)*
- *Exosomes are considered to have minimal immunogenicity; the treatment is off the shelf, not personalized*



# PROTECTING OUR INNOVATIONS

Learn about our U.S. Patent Application  
and the potential for future patents

On January 13, 2023, **NurExone received a notice of allowance from the United States Patent and Trademark Office (USPTO)** for our U.S. Patent Application NO. 17/042,441.

This patent application covers and protects our Exo-PTEN technology, drug composition, and methods for non-invasive intranasal administration of exosome-based treatment.

## Our IP Portfolio consists of:


- Intranasal ExoPTEN (received allowance)
- 2 PCTs on Production and Composition of Matter of our exosomes
- 4 provisional patents on loading technique and siRNA target sequences





# CLEAR PATH TOWARDS CLINICAL TRIALS

Plans for FDA and EMA approval and the near future of clinical trials



The information presented in this slide is forward-looking information which the Company does not commit or undertake to guarantee in any way. Investors should undertake their own risk assessment and analysis. The milestones shown are only an estimate and the actual development steps and/or results may differ from the estimated schedule presented here. The information is intended for illustrative purposes, its achievement is conditional on many factors over which the Company has no influence. The results of the R&D activities may impact the Company's achievements and schedules.



# LEADERSHIP TEAM

---

## INNOVATIVE TECHNOLOGY, EXPERIENCED TEAM

An award-winning scientific team,  
world-renowned cofounders.



Headquartered in Israel and incorporated in Canada the company is led by a team of world-renowned experts in the field of biotech and pharmaceuticals.

The CEO is **Dr. Lior Shaltiel** and its Chairman and co-founder is serial biomed entrepreneur **Yoram Drucker**.


The company's team of experts includes **Dr. Lyora Aharonov** of Technion in Haifa, an expert in biological research who serves as the R&D Director, and an advisory board of scientists led by **Prof. Shulamit Levenberg**, who has received several prizes including the Krill Prize for excellence in scientific research, and **Prof. Nahshon Knoller**, the former head of the neurosurgery department in the largest hospital in Israel, that led 3 clinical SCI studies.



# OUR TEAM



**Lior Shaltiel, PhD**  
Chief Executive Officer



# SCIENTIFIC ADVISORY BOARD

---



**Prof. Gabriel Zeilig, MD**

Prof. Gabi Zeilig is the director of the Department of Neurological Rehabilitation and the National Spinal Cord Injury Rehabilitation Unit at the Sheba Medical Center, Tel Hashomer, Israel since 1999.

[Read More ...](#)



**Prof. Michael Belkin**

Prof. Belkin was the founder of the Eye Research Institute at the Sheba Medical Center who has been involved in the establishment of many medical start-ups.

[Read More ...](#)



**Prof. Shulamit Levenberg**  
Scientific Advisory Board

Prof. Levenberg is the Dean of the Biomedical Engineering Department, Technion. Prof. Levenberg conducts interdisciplinary research on stem cells and tissue engineering

[Read More ...](#)



**Prof. Daniel Offen**  
Scientific Advisory Board

Prof. Offen is the head of the Lab for Neurosciences at the Felsenstein Medical Research Center, Tel Aviv University. He has conducted pioneering work in stem cells and is a co-founder of biotech companies developing gene and cell therapies.

[Read More ...](#)



**Prof. Nahshon Knoller, MD**  
Scientific Advisory Board

Prof. Knoller established and headed the General Trauma at Sheba Medical Center. Dr. Knoller is a Director of the Spine Surgery Unit who treats and analyzes the entire range of spine and head pathologies...

[Read More ...](#)

# DIRECTORS

## ISRAEL



**Ron Mayron**  
Director

Mr. Mayron held managerial positions at Teva Pharmaceutical for 20+ years. He is currently the Chairman of InnoCan Pharma (CSE:INNO).

[Read More ...](#)



**Eyal Flom**  
Director

Mr. Flom has served as the Israeli Pharmaceutical Association legal counsel since April 1995 and is a director of several biotech startups.

[Read More ...](#)



**Dr. Lior Shaltiel**  
CEO

An entrepreneur and distinguished scientist with extensive international experience, specializing in chemical engineering, electrophysiology, pharmacology and drug delivery systems.

[Read More ...](#)



**Yoram Drucker**  
Founder & VP Business Development

Successful Israeli entrepreneur and expert in the establishment of successful Stem cell start-ups. Founder and Director at InnoCan Pharma (CSE:INNO)

[Read More ...](#)

## CANADA



**Oded Orgil, LL.B.**

Mr. Orgil has over 25 years experience in Capital Markets as a Financial Advisor and Senior Executive for both bank owned and national Independent firms.. In his career on Bay Street Oded has participated in over \$10 Billion of capital market transitions and acquisitions.

[Read More ...](#)



**James (Jay) Richardson**

Mr. Richardson has served as CEO or Chairman of several listed public companies and in others CFO and private company situations. He has extensive public company governance experience from over a dozen Board memberships including serving as Interim Chairman of the Argus Corporation.

[Read More ...](#)

# Share Structure

December 31, 2022

|                                    |                   |
|------------------------------------|-------------------|
| <b>Common Shares</b>               | <b>42,855,159</b> |
| <b>Warrants<sup>1</sup></b>        | <b>15,223,806</b> |
| <b>Options<sup>2</sup></b>         | <b>7,691,891</b>  |
| <b>Fully Diluted Share Capital</b> | <b>65,770,856</b> |

1. Exercise Price: \$1.20 CAD; expires between June 2023 and May 2024  
2. Exercise Price: \$0.80 CAD; expires between August 2031 and January 2032

## THE FUTURE IS NOW

Join us on our mission to revolutionize **recovery** from nervous system injuries by **regeneration and rewiring** of neurons.

- A cutting-edge biotech company focused on developing and commercializing innovative exosome-based therapeutics for spinal cord injuries.
- Proprietary exosome production platform, potentially revolutionize medicine delivery for a wide range of diseases and conditions.
- First proprietary therapeutic molecule is ExoPTEN, side by side with a strong platform technology that are under development for building partnerships, licensing out and commercialization.
- Strong leadership team.
- High potential product pipeline, which may position us for growth and success in the future towards partnerships, licensing and commercialization.

REGENERATION. REWIRING. RECOVERY



**Inbar Paz-Benayoun, Adv.**

**Head of Communications and Investor  
Relations**

**+972-52-3966695**

**[info@nurexone.com](mailto:info@nurexone.com)**